The National Institute for Health and Care Excellence (NICE) has issued final guidance recommending Servier UK’s Lonsurf® (trifluridine/tipiracil), within its marketing authorisation, as an option for treating metastatic colorectal cancer.

The National Institute for Health and Care Excellence (NICE) has issued final guidance recommending Servier UK’s Lonsurf® (trifluridine/tipiracil), within its marketing authorisation, as an option for treating metastatic colorectal cancer.

The National Institute for Health and Care Excellence (NICE) has issued final guidance recommending Servier UK’s Lonsurf® (trifluridine/tipiracil), within its marketing authorisation, as an option for treating metastatic colorectal cancer.

Following a single technology appraisal, the treatment is recommended in adults who have had previous treatment with available therapies including fluoropyrimidine-, oxaliplatin- or irinotecan-based chemotherapies, anti-vascular endothelial growth factor (VEGF) agents and anti-epidermal growth factor receptor (EGFR) agents, or when these therapies are not suitable.

Servier welcomed the decision by NICE, which comes four months after the European Commission granted trifluridine/tipiracil a marketing authorisation.

Leave a Comment